NR0B2 and steatosis: In conclusion, dapagliflozin treatment alleviates steatosis and reduces fat accumulation by inhibiting the FXR/SHP/LXRα/SREBP-1c pathway and reducing ChREBP1 expression in the liver of db/db mice.